# C4-MOSART (NCT03431948)

> Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03431948
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: University of Chicago
- Conditions: Cancer
- Interventions: Nivolumab; Cabiralizumab; Urelumab; Stereotactic Body Radiation Therapy
- Enrollment: 60
- Primary outcome: Recommended dose of SBRT given in combination with immunotherapy

## Indexed commentary on C4-MOSART so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=c4-mosart-nct03431948